# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a sing...
Jefferies analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from ...
NVDAMUTSLAHIMSBBAIRIVNAAPLWAYWBAData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
https://hntrbrk.com/hims/
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, Cle...